PMCF Study in Patients With Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated With E-vita OPEN NEO

Aortic Aneurysm Clinical Trial

— NEOS-APAC  

Official title:

NEOS-APAC - Asian Pacific Post-market Clinical Follow-up Study in Patients With Acute or Chronic Aortic Dissection or Aortic Aneurysm Treated With E-vita OPEN NEO

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04986709
• Other study ID #: NEOS-APAC
• Status: Active, not recruiting
• Start date: August 1, 2021
• Est. completion date: March 31, 2027

Study information

• Verified date: February 2024
• Source: JOTEC GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The NEOS-APAC post-market clinical follow-up study is undertaken to demonstrate the safety and clinical performance of E-vita OPEN NEO in the treatment of aneurysm or dissection in the ascending aorta, aortic arch and descending thoracic aorta.

Description:

In this study, patients will be observed who receive an E-vita OPEN NEO implant for the treatment of thoracic aneurysm or acute or chronic thoracic dissection. E-vita OPEN NEO will be implanted according to the instructions for use and at the discretion of the treating physician. Participating physicians will provide their observations collected during routine care for patients treated with E-vita OPEN NEO. Written informed consent, specifically allowing the use of clinical records for this observational study, will be obtained from every patient prior to data collection. The period of data collection will be approximately 24 months from the date of intervention for each patient. Source data verification will be performed on 100% of the patients; data from all the visits that was provided in the database will be reviewed and verified against existing source documents. Complete DICOM image files of the CT scans will be sent to the CoreLab for independent evaluation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 114
• Est. completion date: March 31, 2027
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient´s age is between 18 and 75 years.

• Patient is willing and able to comply with the standard follow-up visits planned after the implantation procedure.

• Patient is willing and able to give informed consent.

• Patient satisfies one of the following categories:

• Patient has acute / subacute aortic dissection and requires repair or replacement of damaged or diseased vessels of the aortic arch (with or without involvement of the ascending aorta), and the descending aorta requires treatment, or, in the opinion of the investigator, the patient would derive clinical benefit from prophylactic treatment of the descending aorta.

• Patient has chronic aortic dissection which requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta, and the patient satisfies one or more of the following criteria:

Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter = 5.5 cm. Patient has aorta diameter < 5.5 cm and a growth rate of = 0.5 cm / year. Patient has ascending aorta diameter = 4.5 cm and requires an aortic valve repair or replacement. Patient has clinical signs of abdominal or peripheral malperfusion.

• Patient has a fusiform or saccular aortic aneurysm which requires repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta, and patient satisfies the following criteria:

Patient has a suitable distal sealing area in the descending thoracic aorta proximal to the celiac trunk.

And in case of fusiform aneurysm one of the following characteristics:

Patient has aortic sinus, or ascending aorta, or aortic arch, or descending aorta diameter = 5.5 cm. Patient has aorta diameter < 5.5 cm and a growth rate of = 0.5 cm / year. Patient has ascending aorta diameter = 4.5 cm and requires an aortic valve repair or replacement.

• Patient is hemodynamically stable without pharmacological support at time of admission to the hospital (stable blood pressure and heart rate, no shock).

Exclusion Criteria:

• Patient is unfit for open surgical repair involving circulatory arrest.

• Patient has known sensitivities or allergies to nitinol, polyester, platinumiridium, or polyethylene.

• Patient has systemic infection.

• Patient has endocarditis or active infection of the aorta.

• Patient has a free ruptured aorta.

• Patient has acute stroke or suspected acute stroke.

• Patient is on inotropes at time of arrival to the hospital.

• Patient needs mitral valve repair or replacement.

• Patient is enrolled or plans to be enrolled in another active study.

• Patient is pregnant or breastfeeding or planning to become pregnant during the course of the study.

• Patient has uncorrectable bleeding anomaly (i.e., thrombocytopenia).

• Patient has an eGFR < 45 ml/min/1.73m2 before the intervention

• Patient has known sensitivity to radiopaque contrast agents that cannot be adequately pre-treated.

• Patient has co-morbidity (i.e. active malignancy (progressive, stable or partial remission)) causing expected survival to be less than 3 years.

• Patient has any other medical, social or psychological problems, that in the opinion of the investigator, preclude the patient from participating in this study.

Related Conditions & MeSH terms

• Aneurysm
• Aortic Aneurysm
• Aortic Dissection

Intervention

Device:
• Open repair
Open repair of the aortic arch and descending aorta with or without involvment of the ascending aorta using a hybrid graft.

Locations

Country	Name	City	State
Australia	Austin Health	Heidelberg	Victoria
Hong Kong	Prince of Wales Hospital (PWH)	Hong Kong
Hong Kong	Queen Mary Hospital	Hong Kong
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam
Korea, Republic of	Ewha Womans University Seoul Hospital	Seoul
Korea, Republic of	Gangnam Severance Hospital	Seoul
Malaysia	Queen Elizabeth Hospital II	Kota Kinabalu
Malaysia	Institut Jantung Negara	Kuala Lumpur
Singapore	National University Hospital	Singapore
Thailand	Siriraj Hospital	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
JOTEC GmbH

Countries where clinical trial is conducted

Australia,  Hong Kong,  Korea, Republic of,  Malaysia,  Singapore,  Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	Rate of all-cause mortality	30-day
Secondary	Mortality	Rate of all-cause mortality	3-6, 12, 24 months
Secondary	Mortality	Rate of aortic related mortality	30-day, 3-6, 12, 24 months
Secondary	Major Adverse Events	Rate of patients who are free from Major Adverse Events (MAEs) (new permanent disabling stroke (mRS = 2 and at baseline mRS < 2), new permanent (> 30 days) paraplegia or paraparesis, reintervention (excluding reoperation for bleeding or planned or unplanned additional intervention), all-cause mortality)	12 months
Secondary	Device technical success	Rate of patients with device technical success	24 hours
Secondary	Procedural success	Rate of patients with procedural success	At discharge, an avarage of 30 days
Secondary	Treatment success	Rate of patients with treatment success	At discharge, an avarage of 30 days, 3-6,12, 24 months
Secondary	Aortic rupture	Rate of patients with aortic rupture	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Additional intervention	Rate of patients with planned or unplanned additional intervention	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Reintervention	Rate of patients with reintervention	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Disabling stroke	Rate of patients with new disabling stroke	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Paraplegia	Rate of patients with new permanent (> 30 days) paraplegia	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Paraparesis	Rate of patients with new permanent (> 30 days) paraparesis	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Renal failure	Rate of patients with renal failure requiring permanent (> 90 days) dialysis or hemofiltration in a patient with a normal pre-procedure serum creatinine level	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Aortic regurgitation	Rate of patients with increase in aortic regurgitation grade of greater than 1 compared to pre-operative measurement	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Stenosis	Rate of patients with stenosis in the supra-aortic head vessels (0 - 30 %, >30 % - 50 %, > 50 % - 70%, > 70%)	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Patency	Rate of patients with patent supra-aortic head vessels	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Migration	Rate of patients with retrograde migration > 10 mm of the distal end of the stented part of E-vita OPEN NEO	3-6, 12, 24 months
Secondary	Integrity	Rate of patients with failure of integrity of the E-vita OPEN NEO	At discharge, an avarage of 30 days, 3-6, 12, 24 months
Secondary	Endoleak type Ib (aneurysm)	Rate of patients with aneurysm that have an endoleak type Ib	3-6, 12, 24 months
Secondary	Endoleak type II (aneurysm)	Rate of patients with aneurysm that have an endoleak type II	3-6, 12, 24 months
Secondary	Endoleak type III (aneurysm)	Rate of patients with aneurysm that have an endoleak type III	3-6, 12, 24 months
Secondary	Endoleak type IV (aneurysm)	Rate of patients with aneurysm that have an endoleak type IV	3-6, 12, 24 months
Secondary	Increasing aortic diameter	Rate of patients with aneurysm that have an increasing maximum aortic diameter in the stented region (E-vita OPEN NEO) compared to first post-operative CT	3-6, 12, 24 months
Secondary	Stable aortic diameter	Rate of patients with aneurysm that have a stable maximum aortic diameter in the stented region (E-vita OPEN NEO) compared to first post-operative CT	3-6, 12, 24 months
Secondary	Decreasing aortic diameter	Rate of patients with aneurysm that have a decreasing maximum aortic diameter in the stented region (E-vita OPEN NEO) compared to first post-operative CT	3-6, 12, 24 months
Secondary	Endoleak type Ib (dissection)	Rate of patients with dissection that have an endoleak type Ib	3-6, 12, 24 months
Secondary	Endoleak II (dissection)	Rate of patients with dissection that have an endoleak type II	3-6, 12, 24 months
Secondary	Endoleak type R (dissection)	Rate of patients with dissection that have an endoleak type R	3-6, 12, 24 months
Secondary	Increasing or stable true lumen size	Rate of patients with increasing (= 5 mm) or stable true lumen in the stented region	3-6, 12, 24 months
Secondary	Stable or decreasing false lumen size	Rate of patients with stable or decreasing (= - 5 mm) false lumen in the stented region	3-6, 12, 24 months
Secondary	Obliterated false lumen in stented region	Rate of patients with obliterated false lumen in the stented region	3-6, 12, 24 months
Secondary	Completely thrombosed false lumen in stented region	Rate of patients with completely thrombosed false lumen in the stented region	3-6, 12, 24 months
Secondary	Partially thrombosed false lumen in stented region	Rate of patients with partially thrombosed false lumen in the stented region	3-6, 12, 24 months
Secondary	Patent false lumen in stented region	Rate of patients with patent false lumen in the stented region	3-6, 12, 24 months
Secondary	Obliterated false lumen between stent and celiac trunk	Rate of patients with obliterated false lumen between the bottom of the stent and the celiac trunk	3-6, 12, 24 months
Secondary	Completely thrombosed false lumen between stent and celiac trunk	Rate of patients with completely thrombosed false lumen between the bottom of the stent and the celiac trunk	3-6, 12, 24 months
Secondary	Partially thrombosed false lumen between stent and celiac trunk	Rate of patients with partially thrombosed false lumen between the bottom of the stent and the celiac trunk	Time Frame: 3-6, 12, 24 months
Secondary	Patent false lumen between stent and celiac trunk	Rate of patients with patent false lumen between the bottom of the stent and the celiac trunk	3-6, 12, 24 months
Secondary	Obliterated false lumen between celiac trunk and aortic bifurcation	Rate of patients with obliterated false lumen between the celiac trunk and the aortic bifurcation	3-6, 12, 24 months
Secondary	Completely thrombosed false lumen between celiac trunk and aortic bifurcation	Rate of patients with completely thrombosed false lumen between the celiac trunk and the aortic bifurcation	3-6, 12, 24 months
Secondary	Partially thrombosed false lumen between celiac trunk and aortic bifurcation	Rate of patients with partially thrombosed false lumen between the celiac trunk and the aortic bifurcation	3-6, 12, 24 months
Secondary	Patent false lumen between celiac trunk and aortic bifurcation	Rate of patients with patent false lumen between the celiac trunk and the aortic bifurcation	3-6, 12, 24 months